Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 19th 2018

Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, explains the current standard of treatment and novel approaches being taken in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

October 18th 2018

EBO October 2018: Clinical Updates

David Bai, PharmD Allison Inserro Laura Joszt, MA Samantha DiGrande Jaime Rosenberg Mary K. Caffrey

October 18th 2018

Managed Care Updates

David Bai, PharmD Allison Inserro Laura Joszt, MA Samantha DiGrande Jaime Rosenberg Mary K. Caffrey

October 18th 2018

The Nobel Prize: Checkpoint Inhibitors

Nobel Prize winner James Allison, PhD, pioneering T-cell researcher, said the award represents the triumph of science and shows the value of research, even if it does not immediately lead to a scientific or commercial success.

October 18th 2018

What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity

AJMC Staff

UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.

October 18th 2018

Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity

Jaime Rosenberg

A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.

October 17th 2018

Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial

Samantha DiGrande

Last week, Bristol-Myers Squibb announced results from the phase 3 CheckMate -331 trial that investigated nivolumab (Opdivo) versus the current standard of care, chemotherapy, in the treatment of patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. The trial found that nivolumab did not significantly increase overall survival compared with chemotherapy.

October 17th 2018

Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.

October 16th 2018

Nurse Practitioners Can Lead the Way in Affecting Colorectal Cancer Screening

A recent survey investigates the role nurse practitioners can play to promote colorectal cancer screening.

October 16th 2018

Squaring Value-Based Payment With Innovation in Oncology

Mary Caffrey

Finding a place for value-based payment with the fast paced innovation in oncology.

October 16th 2018

Medical Marijuana in Cancer Treatment: No Standards of Care, and So Far, No Coverage

Samantha DiGrande

Over the past decade, both recreational and medical marijuana use in the United States has grown tremendously. However, disputes surrounding the legal and ethical implications, safe administration, dispensing, health consequences, and therapeutic indications– albeit based on very limited clinical data– related to its usage abound.

October 15th 2018

Patient Satisfaction Surveys: A Continuous NCODA Initiative for Improvement Within the Oncology Dispensing Practice

Joshua J. Nubla, PharmD Robert D. Orzechowski, MBA Aaron Budge, PharmD

NCODA presents findings from over 700 patient responses across the country to determine patient satisfaction over 4 categories: time, convenience, staff interaction, and overall satisfaction.

October 15th 2018

Survey of NCI-Designated Cancer Centers Finds Most Are Out-of-Network on Exchanges

Alyssa Schatz, MSW Katy Winckworth-Prejsnar, MPH

The National Comprehensive Cancer Network (NCCN) in collaboration with Avalere Health present survey results examining the experiences National Cancer Institute (NCI)-designated cancer centers have had with the marketplaces, the implications for patients' access to cancer care, and proposed policy solutions.

October 14th 2018

Three Genetic Types Drive Higher Prevalence of MM in African Americans

Laura Joszt, MA

Multiple myeloma (MM) occurs 2 to 3 times more frequently in Americans of African descent than in Americans of European descent, and a new study has identified 3 gene types that account for this disparity.

October 14th 2018

ACOs Had No Significant Impact on Spending for Patients With Cancer

Laura Joszt, MA

Accountable care organizations (ACOs) have not had a significant impact on cancer care costs and utilization. While cancer care costs did decline from before the introduction of ACOs to after, there was no significant difference in spending decreases between ACO practices and non-ACO practices caring for patients with cancer.

October 13th 2018

Know the Risk: 5 Breast Cancer Risk Factors

Samantha DiGrande

Here are 5 breast cancer risk factors for Breast Cancer Awareness Month.

October 12th 2018

The US Oncology Network Announces Highly Positive MIPS Results for 2017

Laura Joszt, MA

Practices in the US Oncology Network received an average positive payment adjustment under the Merit-based Incentive Payment System (MIPS) of 1.90% for performance in 2017, and 99% of the Network’s physicians were in the top tier of performers. The maximum allowable adjustment is 2.02%. The adjustment based on a clinician’s performance in 2017 impacts the clinician's Medicare reimbursement for 2019.

October 12th 2018

Nobel Prize Winner Dr James Allison Discusses the Need to Fund More Fundamental Science

Major discoveries only happen when there is funding for fundamental science, said James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine. He explained that he never would have discovered how to use the CTLA-4 protein to treat cancer if he hadn’t been trying to understand the mechanisms of T-cell activation.

October 11th 2018

Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds

Laura Joszt, MA

Tisagenlecleucel's high price is aligned with the benefit the chimeric antigen receptor T-cell therapy provides over a patient's life. Approximately 40% of patients treated are expected to be long-term survivors.

October 10th 2018

NCCN Releases Patient Guidelines for Neuroendocrine Tumors

Samantha DiGrande

This week, the National Comprehensive Cancer Network (NCCN) published new guidelines for patients centered around neuroendocrine tumors.

October 10th 2018

FDA Approves Libtayo to Treat Second Most Common Skin Cancer

Samantha DiGrande

Last week, the FDA granted approval to immune checkpoint inhibitor cemiplimab-rwlc, to be sold as Libtayo, for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), or in patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

October 10th 2018

Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says

Allison Inserro

A medical social network for physicians said it has compiled data that pinpoint the top 50 metropolitan areas where shortages of oncologists are expected to occur in the coming years. Doximity said the findings in its 2018 National Oncologists Workforce report are drawn from retirement trends, the percentage of state-trained specialists, and the prevalence of breast cancer.

October 8th 2018

Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?

David Bai

The development of resistance to immunotherapy is poorly understood and is detrimental to patients who relapse on multiple lines of treatment. Transcriptional downregulation of class 1 human leukocyte antigen (HLA) may contribute to the developed resistance of immunotherapies, including checkpoint inhibitors, and warrants further investigation, according to a study published in Nature Communications.

October 7th 2018

A Comprehensive Look at Updates, Developments in NETs

Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlined the biggest news and updates in the treatment of neuroendocrine tumors (NETs).

October 7th 2018

An Update on Lung NET Guidelines

Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, held October 4-6 in Seattle, Washington, Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, gave an overview of updates made to lung neuroendocrine tumor guidelines.

October 7th 2018

Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses peptide receptor radionuclide therapy and other new and exciting developments in the treatment of neuroendocrine tumors (NETs).

October 6th 2018

Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs

AJMC Staff

A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after octreotide can be a potential therapeutic option.

October 6th 2018

Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape

The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.

October 6th 2018

Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options

Jaime Rosenberg

Narrowing in on neuroendocrine skin cancer, a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, took an in-depth look at prognostics and treatment options for Merkel cell carcinoma in the United States.

October 6th 2018

Debating Best First-Line Treatment in Well-Differentiated G3 NENs

Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.

...

37 38 39 40 41 42 43 44 45

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions